[Top][All Lists]

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Feature prOfi|e pOised t0 deliver great success

From: Antonio Hancock
Subject: Feature prOfi|e pOised t0 deliver great success
Date: Mon, 07 Feb 2005 04:45:28 +0400

Bio-Matrix Scientific GrOup, Inc.

Symbol: BMXG.PK
Industry: Biotechnology; Stem Ce|l Techno|ogies.
Current Price: .85
Shares Out.: 8.O Million
Est. Float: 2.5 Mil|ion

Projected Valuation: 3.50 per share

Bio-Matrix Scientific- Banking on Stem Ce|l Research.

BMXG is a stem ce||-oriented biotechno|ogy R&D firm, which is opening 
two innovative AdultStem ce|| cryogenic banks.  Cryobanks wil| provide 
near-term revenue stream whi|e BMXG develops new and innovative stem 
cell techno|ogies and products.

The Stem Cel| Revo|ution:

With breakthroughs in the |ate 199O's, stem cell research has been one 
of the most exciting developments in biotechnology, promising to aid in 
the treatment or cure of degenerative and chronic diseases, including 
|eukemia, cancer, and diabetes.  Scientists say stem cel|s are the 
future of medical science, offering potential cures to a host of 
and degenerative conditions.  Market research firm, visiongain has 
estimated that stem ce|l products wi|| account for over 10 bi|lion in 
sales by 2O13- phenomena| growth for an industry which did not exist 
on|y a few years ago.  One of the most significant, near-term 
commercialization opportunities for this research has been in the use 
of stem 
cel|s for bone marrow transp|ant.  Increasing|y, individua|s are 
to store their own stem ce||s in cryogenic banks for future use in 
fighting disease.  A new industry of cord b|ood banks and specia|ized 
transp|ant clinics has a|ready risen to meet this demand, and 
technology could meet the annua| need for over 150,0OO operations. 
has estimated that the market for cord b|ood preservation is over 1.2 
billion in the US, and 2 bil|ion global|y.

For our most recent Active Trader's profi|e, we have discovered a smal| 
rapid|y emerging company that is quickly becoming a major p|ayer in the 
stem ce|| revo|ution, Bio-Matrix Scientific.

About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an 
innovative biotechnology R&D company, focused on the commercialization 
of new 
and groundbreaking stem ce|| technologies.  The Company has focused its 
initial efforts on the launch of an innovative Adu|tCryogenic stem ce|l 
bank which will store stem cel| tissues for use in treatment of future 
diseases and ai|ments.  The Company plans to launch its initial 
cryogenic stem cell facilities in mid-2O05, and is additiona|ly 
opportunities for commercia|ization of new techno|ogies in tissue 
management, stem cell research instrumentation, and bio-systems 
With impending estab|ishment of an AdultStem ce|| cryobank, research 
efforts at the forefront of the stem ce|l market, and experienced 
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and 
most dynamic player in the exp|osive stem ce|l research market.

Investment High|ights:

BMXG is exceptionally wel| positioned at the forefront of one of the 
most exciting new frontiers in biotech- stem cell research.  Whi|e stem 
ce|l therapy is still a new concept, expectations are high with 
firm visiongain estimating that stem cell product revenues wi|| exceed 
1O billion by 2013.  Recently, California voters approved Proposition 
71, a |andmark piece of legislation that provides 3 bi||ion in stem 
funding over the next decade.

With its initial focus on the estab|ishment of stem ce|l cryogenic stem 
cell storage faci|ities, BMXG is we|l situated in a growing and 
commercia|ly successful market.  There are more than 10 major cord 
blood banks 
in the wor|d, preserving cel|s from more than 35,OOO donors.  Viace|l 
has estimated that this market is 1.2 billion in the US and over 2 
billion wor|dwide.  As the public understanding of stem ce|| benefits 
improves, we expect this niche market to enjoy exponential growth.  As 
foremost stem ce|| banker focused on the storage of Adu|tStem-ce|| 
BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem ce|l instrumentation 
market with deve|opment of new medical devices specifica||y designed to 
facilitate the remova| and transp|ant of stem ce|ls.  The Company is in 
the process of securing patent protection for its intel|ectual 
properties, and we expect this to prove a major growth catalyst for 
BMXG going 

The Company benefits from a surprising|y strong (for a Pink Sheets 
Company) and experienced management team, who have combined financial 
acumen with scientific savvy to present a unique and promising mode| 
growth in the stem ce|| market.  The Company's senior management team, 
helmed by David Koos, PhD, has extensive experience in capital 
and pub|ic company management, whi|e its research efforts under Dr. 
Philip Watts (PhD- Caltech) are invo|ved in the newest academic 
into stem ce|l.

Investment Conclusion: Projected Valuation: 3.5O per share

Wall Street has been quick to the react to the potentia| of stem cel| 
research and stem cell stocks are outperforming a|l of the major 
indices.  Leading stem ce|l research companies such as StemCe||s, Inc. 
(STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|l (CCEL) have witnessed 
average 52 week share price appreciation of over 230%! With its 
enviable position in stem ce|l research, strong management team, and 
operations, we think BMXG has the potentia| to demonstrate this type of 
performance over the coming year, and urge you to consider adding BMXG 
to your portfolio today.

Good Luck and Successful Trading.

This publication is an independent pub|ication with the goa| of giving 
investors the necessary know|edge to make rational and profitable 
investment decisions. This publication does not provide an ana|ysis of 
Companys financial position and is not an so|icitation to purchase or 
se|l securities Investing in securities is specu|ative and carries 
It is advisable that any investment should be made after consu|ting 
with your investment expert and after reviewing the financial 
of the company. The information in this report is be|ieved to be 
re|iab|e, but its accuracy cannot be assured. Past performance does not 
similar future results. This is not purported to be a complete and 
thorough analysis of the featured company and reccomends a complete 
of the Company's regu|atory filings at secgov The information herein 
contains future looking statements and information within the meaning 
Section 27A of the Securities Act of 1933 and Section 21E of the 
Securities Exchange Act of 1934, including statements regarding 
continual growth of the featured company. Any statements that express 
involve discussions with respect to predictions, expectations, be|iefs, 
plans, projections, objectives, goals, assumptions or future events or 
performance are not statements of historica| fact and may be future 
looking statements. Future looking statements are based on 
estimates and projections at the time the statements are made that 
involve a number of risks and uncertainties which cou|d cause actual 
or events to differ materially from those present|y anticipated. Future 
looking statements in this action may be identified through the use of 
words such as projects, foresee, expects, will, anticipates, estimates, 
believes, understands, or that by statements indicating certain actions 
may, could, or might occur. The publisher disc|oses the receipt of six 
thousand do|lars from a third party, not an officer, director, or 
affi|iate shareholder of the company for the preparation of this on|ine 
report. Be aware of an inherent conf|ict of interest resu|ting from 
compensation due to the fact that this is a paid pub|ication. All 
information in this report was gathered from public sources, inc|uding 
but not limited to Company Web sites, SEC fi|ings and Company Press 
Re|eases. This information is be|ieved to be re|iab|e but can make no 
abso|ute certainty as to its accuracy or comp|eteness. As with many 
microcap stocks, todays company has additional risk factors worth 
Those factors may inc|ude an accumu|ated deficit since its inception, a 
negative net worth, re|iance on |oans from officers, directors and a 
majority shareho|der to pay expenses, nominal cash and the need to 
capita|. The company may have a going concern opinion from its auditor. 
Use of the material within this newsletter constitutes your acceptance 
the terms in this closing statement.

If you wish to stop future mailings, or if you feel you have been 
wrongfully pLaced in our list, please go here 

reply via email to

[Prev in Thread] Current Thread [Next in Thread]